Key result
Long-term captopril therapy for 2 to >4 years in 74 patients with essential hypertension was well tolerated with no resistance, few mild side effects, and 1 case of proteinuria.
Why the study?
Does long-term treatment with captopril maintain efficacy and safety in patients with mild-moderate essential hypertension?
Cohort (n=74)
Does long-term treatment with captopril maintain efficacy and safety in patients with mild-moderate essential hypertension?
Long-term treatment with captopril for mild-moderate essential hypertension is well tolerated without the development of resistance or significant long-term toxicity.
Offers reassurance on long-term captopril tolerability; leaves open confirmation of sustained efficacy and safety in randomized trials.
Seventy-four patients from four short-term studies of captopril in mild-moderate essential hypertension continued in a cooperative long-term efficacy and tolerance program. The duration of observation is 2- greater than 4 years, the total treatment time being 2434 months. No development of resistance to therapy was observed. The total daily dose of captopril has been gradually decreased and in 20 patients changed from t.i.d. to b.i.d. regime. The drug has been well tolerated and only few and mild side-effects have been observed after the initial titration period. The drop-outs (n = 19) were mostly due to non-medical causes (n = 14). Except for one case of proteinuria, no laboratory abnormalities were detected and there were no signs of long-term toxicity.
No takes yet. Share an insight, caveat, or question.
Öhman et al. (1984) conducted a cohort in Mild-moderate essential hypertension (n=74). Captopril was evaluated on Long-term efficacy and tolerance. Long-term captopril therapy for 2 to >4 years in 74 patients with essential hypertension was well tolerated with no resistance, few mild side effects, and 1 case of proteinuria.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: